Volume 10, Issue 1 (2-2023)
JROS 2023, 10(1): 43-48 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Delkash P, Heidari Almasi M, Moradi Shahrbabak H, Ariana S, Vaziri-Harami R. Melatonin Versus Duloxetine for Managing Symptoms of Osteoarthritis: A Randomized Controlled Trial Study. JROS 2023; 10 (1) :43-48
URL: http://jros.iums.ac.ir/article-1-2256-en.html
URL: http://jros.iums.ac.ir/article-1-2256-en.html
Parisa Delkash1 
, Minoo Heidari Almasi1 , Hamideh Moradi Shahrbabak1 , Shideh Ariana2 , Roya Vaziri-Harami 1
, Minoo Heidari Almasi1 , Hamideh Moradi Shahrbabak1 , Shideh Ariana2 , Roya Vaziri-Harami 1
1- Clinical Research Development Unit, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Perinatology Division, Department of Obstetrics and Gynecology, School of Medicine, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Perinatology Division, Department of Obstetrics and Gynecology, School of Medicine, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (65 Views)
Background: Osteoarthritis (OA) is a degenerative joint disorder causing pain and disability. The present treatments are inadequate to improve the underlying pathogenesis of OA. Melatonin, because of its chondroprotective, anti-inflammatory, and antioxidant properties, may have a role in the management of OA. Duloxetine is presumed to modulate pain through serotonergic and noradrenergic pathways. In the present study, as a first study, melatonin has been compared with duloxetine for its efficacy in reducing OA-related knee pain.
Methods: This randomized controlled trial (RCT) study involved 60 knee OA patients treated at Imam Hossein Hospital in Tehran, Iran. Participants were randomly assigned to receive either melatonin, 3-10 mg per day, or duloxetine, 60-120 mg per day. The primary outcome measure was the 3-month change in the Western Ontario and McMaster universities OA index (WOMAC) score.
Results: Compared to the duloxetine group, a reduction in the total WOMAC score was noted in the melatonin group (P=0.001 and P=0.09, respectively). Changes in WOMAC pain score were significant in both groups (P=0.0001). Additionally, the need for naproxen for breakthrough pain was significantly lower in the melatonin group (318.33±16 mg vs 810±35 mg with a P<0.001).
Conclusion: Melatonin is more potent than duloxetine in pain reduction and functional improvement in patients with knee OA. Considering the ability of melatonin to reduce the usage of nonsteroidal anti-inflammatory drugs, melatonin may be a safer agent for managing pain in OA.
Methods: This randomized controlled trial (RCT) study involved 60 knee OA patients treated at Imam Hossein Hospital in Tehran, Iran. Participants were randomly assigned to receive either melatonin, 3-10 mg per day, or duloxetine, 60-120 mg per day. The primary outcome measure was the 3-month change in the Western Ontario and McMaster universities OA index (WOMAC) score.
Results: Compared to the duloxetine group, a reduction in the total WOMAC score was noted in the melatonin group (P=0.001 and P=0.09, respectively). Changes in WOMAC pain score were significant in both groups (P=0.0001). Additionally, the need for naproxen for breakthrough pain was significantly lower in the melatonin group (318.33±16 mg vs 810±35 mg with a P<0.001).
Conclusion: Melatonin is more potent than duloxetine in pain reduction and functional improvement in patients with knee OA. Considering the ability of melatonin to reduce the usage of nonsteroidal anti-inflammatory drugs, melatonin may be a safer agent for managing pain in OA.
Keywords: Osteoarthritis (OA), Melatonin, Duloxetine, Western Ontario and McMaster universities osteoarthritis index (WOMAC)
Type of Study: Research Article |
Subject:
Rheumatology
Received: 2022/07/12 | Accepted: 2022/09/29 | Published: 2023/02/1
Received: 2022/07/12 | Accepted: 2022/09/29 | Published: 2023/02/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
